PURE Bioscience Reports Fiscal First Quarter 2023 Financial Results

RANCHO CUCAMONGA, Calif.--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal first quarter ended October 31, 2022. Summary of Results – Fiscal First Quarter Operations Net product sales were $467,000 and...

Click to view original post